Posts tagged ‘lymphoma’


Childhood cancer: Know the 12 warning signs

September 1, 2014 | by

Childhood cancer survival rates have increased dramatically over the past 40 years. More than 80 percent of children with cancer now survive five years or more, which is a tremendous feat.

Childhood Cancer Awareness Month

Knowing the warning signs of childhood cancer is the first step in getting a diagnosis.

Despite the survival rate increase, cancer continues to be the No. 1 disease killer and second-leading cause of death in children. In 2014, nearly 1,400 children under the age of 15 are expected to die from cancer in the United States and about 10,450 children will be diagnosed with some form of cancer.

Although there are no widely recommended screening tests for childhood cancers, many cancers can be found early. That’s why it’s important to be aware of the signs and symptoms for some of the most common childhood cancers, including acute lymphoblastic leukemia, lymphoma, brain tumors, neuroblastoma and Wilm’s tumor. » Continue Reading


‘Mini’ stem cell transplant: What is it and how does it treat cancer?

August 29, 2014 | by

Although a stem cell transplant can be a lifesaving procedure for people diagnosed with a blood cancer or blood disorder, the standard transplant may not be appropriate for all patients. This is because the conditioning regimen (the intensive chemotherapy and/or radiation treatments preceding the transplant) is very taxing on the body, and certain patients — such as those who are older — cannot tolerate the toxicity associated with the process.

Because non-myeloablative transplants rely on the anti-tumor effects of the donor cells, patients can be treated with a lower dose of chemotherapy and/or radiation—resulting in an easier-to-tolerate treatment regimen with fewer side effects.

Because nonmyeloablative, or “mini,” transplants rely on the anti-tumor effects of the donor cells, patients can be given a lower dose of chemotherapy — resulting in an easier-to-tolerate treatment regimen with fewer side effects.

But at City of Hope, this does not rule them out of a potentially curative transplant, thanks to our care team’s specialization in nonmyeloablative transplants (also known as a reduced intensity, or “mini,” transplant.)

Here, Stephen J. Forman, M.D., the Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, explains how this relatively new procedure works.

What is a nonmyeloablative stem cell transplant and how does it work to treat cancer?

Nonmyeloablative stem cell transplant is a way of doing a transplant that is not as intensive as traditional transplant regimens. It uses lower doses of drugs than a standard transplant but still enables us to engraft stem cells from a donor. It then works through utilizing the donor stem cells, which builds an immune reaction against the residual cancer cells — hopefully eliminating the disease and preventing it from returning.

Because it is less intensive, nonmyeloablative transplants are generally used for patients who are older or otherwise too frail to tolerate a traditional transplant, and this procedure has allowed us to perform curative transplants in a greater range of people. » Continue Reading


Immunotherapy trials use viruses to teach immune cells to fight lymphoma

August 27, 2014 | by

Hijacking the same sorts of viruses that cause HIV and using them to reprogram immune cells to fight cancer sounds like stuff of the future.

virus, antibodies and t-cells

Immunotherapy research at City of Hope is using viruses to program a patient’s own immune cells to fight lymphoma.

Some scientists believe that the future is closer than we think – and are now studying the approach in clinical trials at City of Hope. Immunotherapy is a promising approach for cancer treatment, and while the science is quickly advancing, the idea isn’t exactly new.

In the late 1800s – before much was known about the immune system – William Coley, M.D., a New York surgeon, noticed that getting an infection after surgery actually helped some cancer patients. So he began infecting them with certain bacteria, with positive results.

Today, doctors continue to seek ways to harness the immune system to fight disease. City of Hope researchers are examining immunotherapy techniques to treat some of the toughest cancers including gliomas, ovarian cancer and hematologic cancers. One especially promising approach is called adoptive T cell therapy.

» Continue Reading


For bone marrow transplant patients, outcomes and data matter

August 22, 2014 | by

Nearly four decades ago, City of Hope began its bone marrow transplant program. Its first transplant reunion celebration was a single patient and his donor, also his brother.

BMT Reunion 2014

City of Hope has performed nearly 12,000 hematopoietic cell transplants, and has the best outcomes in the nation. Here are some of our survivors at the 2014 BMT reunion.

This year, City of Hope welcomed hundreds of hematopoietic cell transplant (HCT) recipients to the annual bone marrow transplant/HCT reunion. Since the program’s inception, City of Hope has performed more than 12,000 hematopoietic cell transplants, for patients ranging in age from less than 1 year old to more than 79 years old.

The reunion of bone marrow transplant patients, one of the highlights of the year for City of Hope, underscores the close relationships that City of Hope caregivers have with their patients, even those who have been free of their cancer for decades. The outcomes for the program underscore the importance of those relationships and the high level of expertise provided here: They are among the very best in the nation. » Continue Reading


Adoptive T cell therapy: Harnessing the immune system to fight cancer

August 15, 2014 | by

Immunotherapy — using one’s immune system to treat a disease — has been long lauded as the “magic bullet” of cancer treatments, one that can be more effective than the conventional therapies of surgery, radiation or chemotherapy. One specific type of immunotherapy, called adoptive T cell therapy, is demonstrating promising results for blood cancers and may have potential against other types of cancers, too.

In adoptive T cell therapy, T cells (in blue, above) are extracted from the patient and re-engineered to recognize and attack cancer cells. They are then re-infused back into the patient, where it can then target and kill cancer cells throughout the body. (Photo credit: Lawrence Berkeley Laboratory)

In adoptive T cell therapy, T cells (in blue, above) are extracted from the patient and modified to recognize unique cancer markers and attack the cells carrying those markers. They are then reinfused back into the patient, where they can kill cancer cells throughout the body. (Photo credit: Lawrence Berkeley Laboratory)

Here, Leslie Popplewell, M.D., associate clinical professor and staff physician in City of Hope’s Department of Hematology & Hematopoietic Cell Transplantation, explains what this treatment entails.

What is adoptive T cell therapy and how does it work to treat cancer?

Every day, our immune system works to recognize and destroy abnormal, mutated cells. But the abnormal cells that eventually become cancer are the ones that slip past this defense system. The idea behind this therapy is to make immune cells (specifically, T lymphocytes) sensitive to cancer-specific abnormalities so that malignant cells can be targeted and attacked throughout the body.

Who would be good candidates for this type of therapy? » Continue Reading


With cancer, expertise matters – as these cancer patients know (w/VIDEO)

August 12, 2014 | by

A patient diagnosed with cancer – especially a rare, advanced or hard-to-treat cancer – needs specialized care from exceptionally skilled and highly trained experts. That kind of care saves lives, improves quality of life and keeps families whole.

That kind of care is best found at comprehensive cancer centers like City of Hope.

One of the top cancer hospitals for cancer in the United States, according to U.S.News & World Report’s annual rankings, City of Hope has also been awarded the highest level of accreditation from the American College of Surgeons Commission on Cancer and is listed on Becker’s Hospital Review’s 2014 list of “100 Hospitals and Health Systems With Great Oncology Programs.”

Further, recent research found that receiving cancer care at a comprehensive cancer center improves survival of patients with cancers of the breast, lung, liver, stomach, pancreas and oral tissues, among others.

The cancer patients in the video above don’t need to be convinced by such commendations or research, however. They were convinced by City of Hope itself.

Read more about them:

**

Learn more about becoming a patient or getting a second opinion at City of Hope by visiting us online or by calling 800-826-HOPE (4673). City of Hope staff will explain what’s required for a consult at City of Hope and help you determine, before you come in, whether or not your insurance will pay for the appointment.


Cancer expertise matters. Just ask ex-lymphoma patient Christine Pechera

July 22, 2014 | by

Eleven years ago, lymphoma patient Christine Pechera began the long road toward a cancer-free life.

Christine Pechera unveils 2014 City of Hope Rose Parade Float Rendering at the Wrigley Mansion.

Former lymphoma patient Christine Pechera unveils 2014 City of Hope Rose Parade Float Rendering at the Tournament of Roses – Wrigley Mansion. Her second opinion at City of Hope ultimately led to her remission.

She had been diagnosed with non-Hodgkin lymphoma and told by doctors elsewhere that her lifespan likely would be measured in months, not years. Refusing to give up, she came to City of Hope for a second opinion. There, she received her first encouraging words. She began treatment soon after watching the Tournament of Roses Parade in Pasadena, an event that she’d watched as a child and that she thought she might never see again.

After undergoing chemotherapy, radiation and an autologous stem cell transplant – a procedure using her own stem cells – Pechera returned to health, only to relapse in 2005.

She can still find the YouTube video pleading for help in the search for a matching bone marrow donor. Because she was Filipino, matches were hard to come by; her search was even featured on “Nightline,” highlighting the need for more diversity among donors. Finally, a man in Hong Kong – who never saw the video or “Nightline” – was identified as a match.

His stem cells – and the expertise of City of Hope’s lymphoma experts – saved Pechera’s life. The journey that began with a poor prognosis at another institution brought her back to the Rose Parade on January 1 of this year. This time, the former lymphoma patient rode on City of Hope’s float, paying tribute to the fact that the dream of being cancer-free can be within reach, even in some of the toughest cases. » Continue Reading


A bone marrow transplant on an outpatient basis? For some patients, yes

July 17, 2014 | by

Six, to date; more soon. Outpatient bone marrow transplants, that is.

City of Hope is expanding the transplant services to more patients by delivering care on an outpatient basis.

City of Hope is now providing bone marrow transplant services to some patients on an outpatient basis.

Finding new ways to deliver quality care with the greatest benefit is a priority for a patient-centered institution like City of Hope. For example, not every bone marrow transplant patient needs to check into the hospital for treatment. In fact, some might even benefit from remaining outpatients.

City of Hope’s new day hospital is designed to address their needs.

Studies have shown that day hospitals can meet clinical standards for bone marrow transplants without compromising patient quality of care. They allow patients to be treated as outpatients rather than inpatients, which lets them go home after their treatment. The result can be greater patient satisfaction and an improved patient experience. » Continue Reading


For runner Michele Sturt, this journey began with a lymph node

May 22, 2014 | by

Every patient story is unique and, so in its own way, inspiring. Here, Michele Sturt – a runner, a nurse and a mother of four – shares her story of non-Hodgkin lymphoma and of her ultimate treatment at City of Hope.

**

I was diagnosed with non-Hodgkin lymphoma in 2007 when I was 54 years old. I had been a runner since I was in my early twenties and used running as my gauge to my personal wellness status. How fast, how much effort, how many aches and pains, how many personal bests … these have been my general health parameters for many years. In other words, aside from various weekend warrior accidents, I had been quite healthy until I was told I had non-Hodgkin lymphoma.

patient Michele Sturt

Michele Sturt of Petoskey, Michigan, has long used running as her gauge of personal health. Before she was diagnosed with non-Hodgkin lymphoma, her running signaled to her that something wasn’t quite right. Now, almost a year post-bone marrow transplant at City of Hope, she’s running once more. Here, she runs near a son’s home in Santa Barbara. Photo courtesy of Michele Sturt.

I had noticed that I was really having a hard time keeping up with my running friends. I was working too hard and not getting anywhere fast. I also had a single small inguinal lymph node that was new. It didn’t bother me other than I knew it wasn’t normal. Besides being a runner, I am also a nurse practitioner in internal medicine.

First, I waited the obligatory four to six weeks to see if it would go away. I also complained to one of the doctors I work with, and she felt I should have the node biopsied and be done with it. The general surgeon gave me the option of waiting longer before doing anything, but at that point I wanted the node out and evaluated. I was tired but had no other symptoms.

My diagnosis was non-Hodgkin lymphoma, specifically indolent follicular B cell, a slow-growing, not curable but treatable form of lymphoma.

So, now what? I didn’t feel like I had cancer. I had lived an unusually clean and healthy life, although crazy busy and active, and I was the last person you would expect to have cancer, unless you knew what I knew – it’s a dice throw and I just crapped out. With only one oncologist available in my hometown of Petoskey, Michigan, at that time, I needed to figure out where to go for answers. » Continue Reading


Meet our doctors: Robert Chen on survival of Hodgkin lymphoma

May 17, 2014 | by

Hodgkin lymphoma, also known as Hodgkin disease, is a type of cancer that begins in lymphatic tissue, which includes the lymph nodes and other parts of the body’s immune and blood-forming systems. It affects white blood cells, thus damaging the body’s ability to fight infection. In the United States, 6,000 to 7,000 new cases of Hodgkin lymphoma are diagnosed each year.

City of Hope's Robert Chen

Hodgkin lymphoma specialist Robert Chen says advances in research and treatment of the disease have improved patient survival, and more advances are expected.

Although a diagnosis of Hodgkin lymphoma can be challenging, Robert Chen, M.D., assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope, explains that recent advances in the diagnosis and treatment of the disease are giving patients the chance for a full recovery and long-term survival.

What is Hodgkin lymphoma?

Hodgkin lymphoma is one of the subtypes of lymphoma. Lymphoma arises out of lymphocytes, which are part of the white blood cells in the immune system. They are characterized by the presence of Reed-Sternberg cells when examined microscopically. The disease is considered curable, but a certain percentage of patients are refractory or relapsed to the primary treatment.

Are there any known causes of Hodgkin lymphoma? Also, who is most at risk?

This cancer primary occurs in two age groups – the first in young adulthood (ages 15 to 35), and the second in those over 55. Certain chemical and radiation exposures have been linked to Hodgkin lymphoma. Immunocompromised patients, such as patients with HIV or solid organ transplants, have been associated with having a higher risk. But in general, most patients do not have an identifiable risk factor. » Continue Reading